Current Trends and Advances in Nanoplatforms-Based Imaging for Cancer Diagnosis

基于纳米平台的癌症诊断成像技术的最新趋势和进展

阅读:2

Abstract

The intersection of nanotechnology and biomedical imaging has ushered in a new era in the early detection and diagnosis of cancer which has revolutionized biomedical imaging by enhancing sensitivity, resolution, and targeting capability. This review presents a comprehensive overview of the latest developments and innovations in nanoplatforms-based imaging for cancer diagnosis, a burgeoning field that holds significant potential in improving cancer detection and treatment. Recently multimodal imaging techniques utilizing the unique properties of different types of nanoparticles are providing comprehensive diagnostic information. This multi-pronged approach allows for more precise tumor localization, size estimation, and growth rate calculation, offering a holistic view of the tumor and its environment. The primary focus of this review is on the recent progress in various types of nanoparticle-based imaging modalities, including optical, magnetic resonance, ultrasound, and nuclear imaging. Specific advancements in nanomaterial design for targeted imaging are highlighted, showing the improvement of precision targeting as an impact on the detection of cancer cells, even in early-stage tumors. A keen examination on the integration of diagnostic and therapeutic capabilities into single nano-based platforms for theranostics, underscoring their potential in personalized medicine is provided. The current challenges in the field, such as issues related to toxicity, biodistribution, and clearance of nanoparticles, and it explores ongoing research aimed at overcoming these hurdles. The growing body of research in this field highlights the promising future of nanoplatforms in improving the early detection and treatment of cancer.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。